Shares of Novo Nordisk plunged Monday after clinical trial results for its highly anticipated weight-loss drug, CagriSema, fell short of expectations. The setback casts a shadow over the pharmaceutical giant, which has recently seen booming sales of its popular medications Wegovy and Ozempic, and raises questions about its ability to maintain its dominance in the rapidly expanding market for obesity treatments. The disappointing data sent Novo Nordisk’s stock price down 16.5% in Copenhagen, the lowest level since June 2021, and erased nearly 60% of its value over the past year.
CagriSema, a weekly injection, combines cagrilintide – which mimics the pancreatic hormone amylin – with semaglutide, the active ingredient in Wegovy and Ozempic. The combination was designed to deliver even greater weight loss than its predecessors by suppressing appetite and increasing feelings of fullness. The trial aimed to demonstrate that CagriSema was at least as effective as Eli Lilly’s Zepbound, which contains tirzepatide, a leading competitor in the anti-obesity drug market. However, the results revealed a less dramatic effect.
The late-stage study, involving 809 participants, showed an average weight loss of 23% after 84 weeks with CagriSema, compared to 25.5% weight loss observed in patients taking tirzepatide. Novo Nordisk stated that the drug “did not achieve its primary endpoint of demonstrating non-inferiority on weight loss for CagriSema compared to tirzepatide after 84 weeks,” according to a company announcement. This difference, though seemingly small, proved significant to investors.
A Competitive Landscape Shifts
The results have prompted analysts to reassess Novo Nordisk’s position in the weight-loss market. Søren Løntoft Hansen, a senior analyst at Denmark’s AL Sydbank, described the outcome as “a swing and a miss,” adding that it’s “difficult to assess whether this data will influence Novo Nordisk’s decision to launch CagriSema on the market.” The news simultaneously boosted Eli Lilly’s stock, which rose 4.3% on Wall Street, signaling a potential shift in investor confidence towards the competitor.
Novo Nordisk has faced increasing pressure to maintain its momentum as Eli Lilly gains ground. The company has already slashed its profit and sales estimates several times in recent months. The company had been counting on CagriSema, along with its recently launched Wegovy pill in the US, to revitalize sales and fend off competition. Analysts at UBS had previously lowered their peak sales forecast for Novo’s GLP-1 drugs from $80 billion to $75 billion by 2032, citing earlier disappointing results from the CagriSema trials.
Doubts About Future Prospects
The sentiment among some analysts is decidedly pessimistic. Emmanuel Papadakis at Deutsche Bank reportedly told Novo management during an investor call that CagriSema now appears “somewhat obsolete” as an upgrade to semaglutide or a competitor to tirzepatide. Despite this assessment, Novo Nordisk CEO Mike Doustdar defended the drug, calling it “a fantastic drug” and asserting that it will still offer the “best weight-loss label [of] any marketed product” when it reaches the market as the first amylin-based product.
Novo Nordisk is pinning some hope on the results of another study examining a higher dose of CagriSema. The company has already submitted the medication to the US Food and Drug Administration (FDA) for approval based on earlier trial data and anticipates a decision later this year. The future of CagriSema, however, remains uncertain.
The Broader Implications for Weight-Loss Treatments
The development with CagriSema underscores the intense competition within the pharmaceutical industry to develop effective and innovative obesity treatments. The shift from injections to pills, as exemplified by Novo Nordisk’s new Wegovy pill, is further reshaping the landscape, expanding options for patients and intensifying the rivalry between major pharmaceutical companies. The demand for these medications is driven by the growing global obesity epidemic and the associated health risks.
The current generation of weight-loss drugs, including Wegovy, Ozempic, and Zepbound, have demonstrated significant efficacy in clinical trials, but they as well come with potential side effects and are often expensive, raising questions about accessibility and affordability. The ongoing research and development efforts aim to address these challenges and create more effective, tolerable, and accessible treatments for obesity.
Novo Nordisk’s next key milestone will be the FDA’s decision on CagriSema, expected later in 2026. Investors and healthcare professionals will be closely watching for any further data from the higher-dose study and assessing the potential impact on the company’s future growth.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical or financial advice. Consult with a qualified healthcare professional or financial advisor for any health concerns or before making any decisions related to your health or finances.
What are your thoughts on the future of weight-loss medications? Share your comments below and let us know what you consider.
